Market Place
Sourcing Support
Antibe Announces FDA Clinical Hold on Otenaproxesul and Legal Action by Nuance
02 Apr 2024 //
FINANCIAL TIMES
Antibe to Present Otenaproxesul PK/PD Results at the ASRA Pain Medicine Meeting
20 Mar 2024 //
BUSINESSWIRE
Antibe Receives Approval to Initiate PK/PD Study of Otenaproxesul
28 Sep 2023 //
BUSINESSWIRE
Antibe Provides Development Update for Otenaproxesul
12 Oct 2022 //
BUSINESSWIRE
Antibe Academic Collaborator to Present Clinical Data at PAINWeek 2022
06 Sep 2022 //
BUSINESSWIRE
Antibe Therapeutics Reports Q1 2023 Interim Financial and Operating Results
15 Aug 2022 //
BUSINESSWIRE
Antibe Therapeutics Outlines Plan for Otenaproxesul`s Acute Pain Program
01 Nov 2021 //
BUSINESSWIRE
Antibe Therapeutics Provides Update on Otenaproxesul and Expanded Drug Pipeline
14 Oct 2021 //
BUSINESSWIRE
Antibe Provides Update on Ph2B Dose-Ranging, Efficacy Study for ATB-346
27 Aug 2019 //
BUSINESSWIE
Ph2B GI Safety Results For ATB-346 Published in British Journal of Pharmacology
16 Apr 2019 //
PR NEWSWIRE
Antibe Therapeutics Announces $5 Million Bought Deal Offering
04 Feb 2019 //
BUSINESSWIRE
Antibe Therapeutics` Successfully Completes Part I of Ph 2B Study for ATB-346
28 Nov 2018 //
BUSINESSWIRE
Antibe Therapeutics Receives Approval to Initiate Phase 2B Study for ATB-346
10 Oct 2018 //
BUSINESSWIRE
Antibe Therapeutics Announces Licensing Deal for Lead Drug in South Korea
05 Sep 2018 //
BUSINESSWIRE
Antibe Therapeutics Provides Clinical Development Update on Its Lead Drug
31 Jul 2018 //
BIOSPACE
Antibe Therapeutics Announces Successful Phase 2B GI Safety Study
20 Mar 2018 //
BIOSPACE
Antibe Therapeutics Announces Enrollment of Final Subjects in Ph2B Gastro
29 Jan 2018 //
BUSINESSWIRE
Antibe Therapeutics Announces Completion Of Validation Studies Of ATB-346
21 Dec 2015 //
BIOSPACE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.